Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

After the 20th week of pregnancy, either new-onset high blood pressure or worsening of existing high blood pressure accompanied by protein in the urine is defined as preeclampsia. Before 20 weeks ...

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...

Merck was founded in 1668 and is the world’s oldest operating chemical and pharmaceutical company. Asuka Koda covers the Yale ...

Merck's diversified pipeline includes promising oncology candidates and a new pneumococcal vaccine, but lacks a ready-made Keytruda replacement. Investors should monitor R&D updates closely ...

Swedish Orphan Biovitrum's (SOBIV.ST), opens new tab preventive RSV therapy Synagis is also available as a monthly injection. Merck reported on Thursday that clesrovimab had a comparable safety ...

Oct 23 (Reuters) - Merck (MRK.N), opens new tab has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm ...

Merck’s (NYSE:MRK) blockbuster cancer therapy Keytruda (pembrolizumab) has been cleared by the European Commission to treat two new indications in gynecologic cancers. The first approval is for ...

The buyout tails Merck's larger M&A move last year, when it bought Prometheus Biosciences and its late-stage bowel disease antibody for $10.8 billion. The New Jersey-based pharma followed that up ...

Merck Research Laboratories. "These approvals underscore the continued expansion of the use of KEYTRUDA in diverse patient populations and treatment settings with utility of KEYTRUDA ranging from ...